IDEXX Laboratories focuses on long-term growth, shares in NASDAQ-100 healthcare peer group

IDEXX Laboratories is positioned as a diagnostics specialist with a clear long-term strategy. The company sits in the NASDAQ-100 and competes with major healthcare peers in veterinary and lab diagnostics.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 09:04.

IDEXX Laboratories (US45168D1046) is a long-standing member of the NASDAQ-100 and develops diagnostic solutions mainly for veterinary practices and laboratories. The stock sits in the U.S. healthcare and diagnostics sector alongside names such as Thermo Fisher Scientific and Zoetis.

Long-term positioning and growth strategy

IDEXX Laboratories builds its business around recurring diagnostics and software revenues, particularly in companion animal health, water testing, and reference laboratory services. The company has historically targeted high single-digit to low double-digit organic revenue growth through expansion of test menus and instrument placements.Company overview on the IDEXX website

In recent years IDEXX Laboratories has emphasized investments in R&D to broaden its diagnostic portfolio and strengthen digital tools for veterinary clinics. The strategic focus includes expanding global reach in markets such as Europe and Asia and deepening integration of practice management software with in-clinic analyzers.Reuters coverage of IDEXX strategic focus

Role in the veterinary and diagnostics sector

IDEXX Laboratories operates in the growing veterinary diagnostics segment, where demand is supported by rising pet ownership and increased spending on animal health care. The company competes with firms such as Zoetis in diagnostics and broader animal health solutions, and with Thermo Fisher Scientific in certain laboratory testing technologies.Financial Times analysis of animal health companies

The veterinary diagnostics market has been characterized by relatively stable growth and a high proportion of recurring revenue from consumables and lab services. IDEXX Laboratories has built a business model around installed instruments in clinics, supported by ongoing demand for reagents and testing services, reinforcing its long-term revenue visibility.Bloomberg commentary on veterinary diagnostics trends

What the company sells

IDEXX Laboratories generates most of its revenue from diagnostic instruments and consumables for veterinary practices, including in-clinic analyzers for blood chemistry and hematology, plus SNAP test kits for infectious disease screening. The company also runs reference laboratories that perform more complex tests for clinics and hospitals.IDEXX description of veterinary diagnostic instruments

Where the stock trades today

The IDEXX Laboratories shares (US45168D1046) trade on NASDAQ under the ticker IDXX; a recent quote on a European platform showed around 482 euros for the shares in euro terms, reflecting their NASDAQ-100 membership and healthcare sector positioning.Finanzen100 price overview for IDEXX Laboratories

IDEXX Laboratories at a glance

• Company: IDEXX Laboratories Inc.
• ISIN: US45168D1046
• WKN: 888210
• Ticker: IDXX
• Trading venue: NASDAQ
• Price (as of 2026-06-26, 16:00): 551.50 USD
• Market cap: approximately 45 billion USD (as of 2026-06-26)
• Sector / industry: Health Care - Life Sciences Tools & Services
• Index membership: NASDAQ-100
• Next earnings date: not officially scheduled

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.